First for Women on MSN17d
La La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'
Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the chronic skin condition. Plaque psoriasis-often mistaken for dry skin or ...
Medscape27d
Topical Psoriasis Therapies: Tapinarof, Roflumilast, and Newer Fixed Combination Topicals Show Robust Efficacy
according to the analysis of patients with plaque psoriasis. “We typically don’t think about putting cream on the scalp,” she added, but additional research looking at this PAD-formulated ...
Medscape6d
Significant Improvement in Psoriasis Observed With Novel Oral Drug Icotrokinra, in Phase 3 Trial
Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...
Healthline28d
Overview of Generalized Pustular Psoriasis
Generalized pustular psoriasis is a very rare and extreme form of psoriasis. It’s characterized by reoccurring flare-ups that cause pus-filled bumps and red or discolored skin over a large part ...
The American Journal of Managed Care11d
Deucravacitinib Improves Quality of Life in Patients With Scalp Psoriasis
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...
Healio11d
Positive results showcase icotrokinra’s ‘unique’ mechanism of action in plaque psoriasis
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
Healio14d
‘Strong data’ support ESK-001’s potential as oral treatment for plaque psoriasis
Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, according to a presentation at the American Academy of Dermatology Annual ...
Medindia16d
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...
Fierce Biotech13d
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Business Insider15d
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Accessed March 2025. viii Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the ...
manilatimes17d
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1 ... for FDA approval based on the PDUFA for the treatment of scalp and body psoriasis, the ...
Morningstar17d
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis ... based on the PDUFA for the treatment of scalp and body psoriasis, the potential for clinical results for ZORYVE ...